A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis

Inclusion Criteria

• •Males or females weighing ≥10 kg and ≥2 and \<18 years old at the time of consent for screening.
• •Have moderate to severe UC.
• •Have failed corticosteroids, biologics, (for example, anti-tumor necrosis factor (TNF) antibodies or anti-integrin antibodies), immunomodulators (for example, azathioprine, thiopurines or methotrexate) or Janus Kinase (JAK)-Inhibitor treatment.
• •Have UC at least 3 months in duration before baseline, which includes endoscopic evidence of UC corroborated by a histopathology report.